| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0920-1211(95)00101-8 |
| P698 | PubMed publication ID | 8739124 |
| P2093 | author name string | H H Wolf | |
| J Engel | |||
| W Löscher | |||
| H S White | |||
| R Bartsch | |||
| C Tober | |||
| E E Polymeropoulos | |||
| C Rundfeldt | |||
| D Hönack | |||
| A Rostock | |||
| B Kutscher | |||
| P433 | issue | 3 | |
| P304 | page(s) | 211-223 | |
| P577 | publication date | 1996-04-01 | |
| P1433 | published in | Epilepsy Research | Q15746405 |
| P1476 | title | D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. | |
| P478 | volume | 23 |
| Q73371173 | A ketogenic diet has different effects upon seizures induced by maximal electroshock and by pentylenetetrazole infusion |
| Q46947143 | A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons. |
| Q53193958 | Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips. |
| Q40745093 | Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. |
| Q43683699 | Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. |
| Q34114419 | Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats |
| Q57921983 | Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket |
| Q42955356 | Anticonvulsant Effect of Antiaris toxicaria (Pers.) Lesch. (Moraceae) Aqueous Extract in Rodents |
| Q38974450 | Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? |
| Q36655604 | Antiepileptic drugs in development |
| Q36958975 | Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study |
| Q42619127 | Atypical gating of M-type potassium channels conferred by mutations in uncharged residues in the S4 region of KCNQ2 causing benign familial neonatal convulsions. |
| Q37878206 | Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update |
| Q24674102 | Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells |
| Q77893179 | Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells |
| Q35717049 | Clinical utility of adjunctive retigabine in partial onset seizures in adults. |
| Q36144410 | Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy |
| Q38371584 | Coexpression and activation of TRPV1 suppress the activity of the KCNQ2/3 channel |
| Q36498532 | Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers |
| Q33422564 | Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. |
| Q24634116 | Discovery, Synthesis, and Structure–Activity Relationship of a Series of N -Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener |
| Q24675330 | Diverse mechanisms of antiepileptic drugs in the development pipeline |
| Q44408542 | Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells |
| Q52974740 | Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. |
| Q43590386 | Effects of retigabine on rhythmic synchronous activity of human neocortical slices |
| Q46857416 | Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo |
| Q53166134 | Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy |
| Q41942478 | Efficacy of Retigabine on Acute Limbic Seizures in Adult Rats |
| Q37302567 | Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults |
| Q34688725 | Emerging drugs for epilepsy |
| Q37058186 | Enhancement of inhibitory neurotransmission and inhibition of excitatory mechanisms underlie the anticonvulsant effects of Mallotus oppositifolius |
| Q85016585 | Ezogabine (retigabine) |
| Q35052160 | Ezogabine: a new angle on potassium gates |
| Q38044694 | Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults |
| Q47149739 | Flupirtine and diazepam combination terminates established status epilepticus: results in three rodent models |
| Q74317079 | Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells |
| Q34458405 | Future prospects for the drug treatment of epilepsy. |
| Q48250335 | GluN2B-containing NMDA receptors promote glutamate synapse development in hippocampal interneurons |
| Q37996815 | HCN and KV7 (M-) channels as targets for epilepsy treatment |
| Q28080655 | Homeostasis or channelopathy? Acquired cell type-specific ion channel changes in temporal lobe epilepsy and their antiepileptic potential |
| Q42449315 | Inhibition of cAMP response element-binding protein reduces neuronal excitability and plasticity, and triggers neurodegeneration |
| Q36989788 | Inside job: ligand-receptor pharmacology beneath the plasma membrane |
| Q48201175 | Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. |
| Q34075106 | Is there a role for potassium channel openers in neuronal ion channel disorders? |
| Q46387953 | Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. |
| Q37162392 | K+ channel modulators for the treatment of neurological disorders and autoimmune diseases |
| Q46935266 | KCNQ/Kv7 channel regulation of hippocampal gamma-frequency firing in the absence of synaptic transmission. |
| Q40802799 | KCNQ4 channel activation by BMS-204352 and retigabine |
| Q51532244 | Kv7 (KCNQ) channel openers induce hypothermia in the mouse |
| Q48472286 | Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release. |
| Q42760045 | Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects |
| Q37642003 | Management of the patient with medically refractory epilepsy. |
| Q24683346 | Molecular targets for antiepileptic drug development |
| Q40144001 | MrgD activation inhibits KCNQ/M-currents and contributes to enhanced neuronal excitability. |
| Q33845614 | Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers |
| Q24644947 | Neural KCNQ (Kv7) channels |
| Q92532747 | Neurobiology of organophosphate-induced seizures |
| Q35683922 | Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. |
| Q27007942 | New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapy |
| Q34119473 | New anti-epileptic drugs |
| Q36600282 | Novel anticonvulsant drugs targeting voltage-dependent ion channels |
| Q34974862 | Novel anticonvulsant medications in development |
| Q37950518 | Novel medications for epilepsy |
| Q36603168 | One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders |
| Q35102221 | Oxidative modification of M-type K(+) channels as a mechanism of cytoprotective neuronal silencing |
| Q45143751 | Paradoxical cerebral cortical hyperexcitability following flupirtine overdose |
| Q34464180 | Pathways modulating neural KCNQ/M (Kv7) potassium channels |
| Q35761335 | Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis |
| Q47270986 | Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy. |
| Q97420402 | Pharmacological Manipulation of K v 7 Channels as a New Therapeutic Tool for Multiple Brain Disorders |
| Q34823174 | Pharmacological management of epilepsy: recent advances and future prospects |
| Q51527954 | Pharmacophore modeling, 3D-QSAR, and in silico ADME prediction of N-pyridyl and pyrimidine benzamides as potent antiepileptic agents. |
| Q37831297 | Pharmacotherapy of epilepsy: newly approved and developmental agents |
| Q37992162 | Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate |
| Q24545908 | Polarized axonal surface expression of neuronal KCNQ channels is mediated by multiple signals in the KCNQ2 and KCNQ3 C-terminal domains |
| Q35035323 | Potassium channels as anti-epileptic drug targets |
| Q34558128 | Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs |
| Q26850811 | Preclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial design |
| Q30527828 | Preclinical research in Rett syndrome: setting the foundation for translational success. |
| Q35117817 | Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures |
| Q43515162 | Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). |
| Q44154771 | Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). |
| Q71864613 | Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference |
| Q77292948 | Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) |
| Q44194876 | Quinine suppresses extracellular potassium transients and ictal epileptiform activity without decreasing neuronal excitability in vitro |
| Q37074600 | Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy |
| Q36697501 | Retigabine |
| Q37936428 | Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy |
| Q38006978 | Retigabine for partial onset seizures. |
| Q73318360 | Retigabine strongly reduces repetitive firing in rat entorhinal cortex |
| Q34333196 | Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data |
| Q34415600 | Retigabine: chemical synthesis to clinical application. |
| Q24685444 | Retigabine: has the orphan found a home? |
| Q34541901 | Retigabine: in partial seizures |
| Q44349595 | Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex |
| Q42594000 | Thalamic Kv 7 channels: pharmacological properties and activity control during noxious signal processing |
| Q35872543 | The Effects of the KCNQ Openers Retigabine and Flupirtine on Myotonia in Mammalian Skeletal Muscle Induced by a Chloride Channel Blocker |
| Q58258271 | The Kv7 potassium channel activator retigabine decreases alcohol consumption in rats |
| Q44791007 | The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation |
| Q53920348 | The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation. |
| Q37973378 | The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy |
| Q34305846 | The mechanisms of action of commonly used antiepileptic drugs |
| Q36675813 | The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential. |
| Q34447899 | The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells |
| Q34320951 | The new generation of GABA enhancers. Potential in the treatment of epilepsy |
| Q28138343 | The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits |
| Q34393213 | The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy |
| Q45906577 | The preclinical discovery and development of ezogabine for the treatment of epilepsy. |
| Q46886423 | The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine |
| Q37973453 | The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. |
| Q35593939 | The therapeutic potential of neuronal KCNQ channel modulators |
| Q37994720 | The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels |
| Q57544107 | The value of blind screening in the Anticonvulsant Screening Program |
| Q28245021 | Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions |
| Q34402797 | Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370 |
| Q34390785 | Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration |
| Q40145551 | Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants |
Search more.